Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease

Citations Over TimeTop 10% of 2007 papers

Abstract

A design strategy to convert a dual-binding site AChE inhibitor into triple functional compounds with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed. The lead compound bis(7)-tacrine (2) was properly modified to confer to the new molecules the ability of chelating metals, involved in the neurodegenerative process. The multifunctional compounds show activity against human AChE, are able to inhibit the AChE-induced amyloid-beta aggregation, and chelate metals, such as iron and copper.

Related Papers

• → Synthesis of New Indole Derivatives Structurally Related to Donepezil and Their Biological Evaluation as Acetylcholinesterase Inhibitors(2012)55 cited
• → Selective Acetylcholinesterase Inhibitor Activated by Acetylcholinesterase Releases an Active Chelator with Neurorescuing and Anti-Amyloid Activities(2010)48 cited
• → The synthesis and anti-acetylcholinesterase activities of (+)-physostigmine and (+)-physovenine(1970)40 cited
• → Acetylcholinesterase Inhibitor(2020)1 cited
• → Effects of Chrysanthemum indicum Linne Flowers on the Acetylcholinesterase Activity and the Learning Performance of Mouse(2008)